News release: Engineering innovation brings hope for a Parkinson’s cure (docx)

Global engineering company Renishaw has built a device that has been used in a ground-breaking clinical trial. Manufactured by Renishaw on behalf of the North Bristol NHS Trust, the device enabled the precise delivery of a new drug candidate, Glial Cell Line Derived Neurotrophic Factor (GDNF) with the hope of regenerating dying dopamine brain cells in people with Parkinson’s and thereby improve their symptoms.